Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.
Search results for: hospital
Summer 2025’s Awards, Appointments & Announcements in the World of Rheumatology
Sharad Lakhanpal, MBBS, MD, Receives India’s Highest Honor for Overseas Indians In early January, Sharad Lakhanpal, MBBS, MD, MACR, FACP, a rheumatologist at Rheumatology Associates in Dallas and past president of the ACR, was one of only three Indian-Americans to receive the 2025 Pravasi Bharatiya Samman Award (PBSA). The award is conferred every two years…
The Hitchhiker’s Guide to Your Post-Fellowship Career
A second-year fellow describes the process of searching for a post-fellowship job in rheumatology.
Reactive Arthritis: Chronic or Self-Limiting?
Reactive arthritis has proved to be a diagnostic & therapeutic challenge due to its diverse presentations.
One Rheumatologist’s Sabbatical for Contemplative Leisure
The year before my hike, I was extremely busy with various ACR workforce issues; meetings; presentations, locally, regionally and nationally; juggling medical missions and more. However, I had blocked time in my calendar over one year in advance to hike the Camino de Santiago in Spain with a long-time U.S. Army buddy. I met Pat…
Rheuminations: The Metaphors, Mythologies & Rituals of Medicine
“Doctor, I hate to tell you this but that shelf is definitely not made of wood,” my patient gently chided me as I knocked on a plastic piece of shelving. “I know … but you get the point,” I replied with a small laugh. It’s become a habit of mine over the past few years…
Psychosocial Factors & Pain in Hand Osteoarthritis
Attention to factors beyond the standard nociceptive model of painin patients with hand OA, including psychosocial considerations &other comorbidities, may impact a patient’s pain perception &pain course.
FDA Approvals: Lupus Nephritis
Lupus nephritis is one of the leading causes of mortality for patients with systemic lupus erythematosus (SLE), and patients with both SLE and end-stage renal disease have standardized mortality ratios more than 60 times that of patients with SLE with normal kidney function.1 The good news: Rheumatologists now have not one, but two approved options…
Trials Find Potential Treatments for SLE, Lupus Nephritis
In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…
Belimumab Promising for Children with Lupus Nephritis
In late July 2022, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children with active lupus nephritis aged 5 to 17 years old receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement may develop endstage renal disease and…
- « Previous Page
- 1
- …
- 6
- 7
- 8
- 9
- 10
- …
- 326
- Next Page »